Research programme: specific immunotherapy vaccines - TheVax

Drug Profile

Research programme: specific immunotherapy vaccines - TheVax

Alternative Names: HPV16/18 Bivalent; Specific ImmunoTherapy - TheVax; THEVAX HBV vaccine; TVGV-2; TVGV-HB; TVGV-HBV; TVGV-HC; TVGV-LC

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TheVax
  • Class Antineoplastics; Antivirals; Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cervical cancer; Hepatitis B; Liver cancer; Lung cancer
  • Research Hepatitis C

Most Recent Events

  • 30 Apr 2018 TheVax signs manufacturing agreement with Biotechpharma for cGMP production of TVGV HBV vaccine
  • 30 Apr 2018 TheVax plans clinical development for Hepatitis B
  • 20 Oct 2017 Pharmacodynamics and safety data from a preclinical trial in Hepatitis B presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top